Glial scarring following severe tissue damage and inflammation after spinal cord injury (SCi) is due to an extreme, uncontrolled form of reactive astrogliosis that typically occurs around the injury site. The scarring process includes the misalignment of activated astrocytes and the deposition of inhibitory chondroitin sulfate proteoglycans. Here, we first discuss recent developments in the molecular and cellular features of glial scar formation, with special focus on the potential cellular origin of scar-forming cells and the molecular mechanisms underlying glial scar formation after SCi. Second, we discuss the role of glial scar formation in the regulation of axonal regeneration and the cascades of neuro-inflammation. Last, we summarize the physical and pharmacological approaches targeting the modulation of glial scarring to better understand the role of glial scar formation in the repair of SCi.
Introduction
Spinal cord injury (SCi) is a common and devastating central nervous system (CNS) insult that results in disruption of cord microstructure and is followed by limited neuronal regeneration and insufficient functional recovery in adult mammals. After severe SCi, and in response to changes in the local microenvironment, astrocytes, the most abundant glial cells in the CNS, transform into reactive astrocytes and undergo dramatic morphological changes [1] as well as massive variations in gene expression [2] . Reactive astrocytes, the major component of glial scars, along with other cells in the spinal cord and blood-borne cells leaking from the damaged blood-spinal cord barrier, participate in the process of scar formation [3] .
From the historical perspective, a glial scar is recognized as an impediment to the regeneration of axons in the cord because of the irregular rearrangement of hypertrophic astrocytic processes, as well as major components of the axonal inhibitory extracellular matrix (ECM), including chondroitin sulfate proteoglycans (CSPGs) that are secreted by the reactive astrocytes [4] . Currently, increasing evidence is advancing our knowledge of the mechanism of the formation of glial scars after a lesion and the roles of glial scars in the regulation of neuro-inflammation and repair processes [5, 6] .
This article reviews the following: (1) the molecular and cellular properties of glial scar formation following SCi;
(2) the roles of glial scar formation in axonal regeneration and neuro-inflammation; and (3) the current status of scarmodulating therapeutic strategies for spinal cord repair after injury.
Molecular and Cellular Properties of Glial Scars

Characterization of Glial Scars
Traumatic damage of the spinal cord can result in seallike scar tissue in the lesion zone, which is filled with dense cellular components and a connective matrix. Generally, the scar tissue is classified into two parts, fibrotic and glial. 
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The fibrotic scar, primarily composed of invading fibroblasts derived from perivascular and meningeal cells, occupies the epicenter of the lesion area, with sedimentation of collagen matrix [7] . Close to the outer layer of the fibrotic scar, a specialized structure is found, the glial limiting membrane, which marks the interface between the fibrotic scar and glial scar tissue [8] . The glial scar (mainly astrocytic) evolves from the dynamic process of reactive gliosis, which is characterized by complicated and meshlike processes extended by reactive astrocytes converging on the peri-lesion zone, thus building a physical barrier to axonal growth after SCi. it is noteworthy that the glial scar has a spatial orientation. Magnetic resonance imaging has revealed that the mean thickness of the glial scar rostral/ caudal to the cavity is thicker than that in the region lateral to the cavity formed in rat spinal cord [9] .
Another important feature of the glial scar is the increased expression of ECM components, which are predominantly secreted by reactive astrocytes. Among the ECM components, the CSPGs and the nature of their inhibition of axonal regeneration and restriction of plasticity have been studied extensively [10] [11] [12] . After injury to the rat spinal cord, there is increasing expression of members of the CSPG family, including neurocan, versican, brevican and NG2 [13, 14] . in humans, after SCi, the CSPG family members NG2 and phosphacan are both detectable in the evolving astroglial scar, while neurocan and versican exist exclusively in the lesion epicenter [15] . Mediated by Rho kinase, CSPGs inhibit neurite growth in vitro and in vivo [16] .
Recently, Siebert and osterhout found that CSPGs directly suppress the process outgrowth from oligodendrocyte progenitor cells (oPCs) and their differentiation into mature oligodendrocytes in vitro [17] . interestingly, CSPGs also control the activity of resident microglia and infiltrating blood-borne monocytes via the CD44 receptor, thus playing a beneficial role in the acute phase of SCI [18] .
in general, the formation of the glial scar depends on the severity of the lesion, as severe trauma can give rise to a permanent glial scar in the affected region. in addition, the disparity of astrocytic location within the spinal cord can also influence the development of glial scars. Astrocytes proximal to the lesion site densely overlap newlyproliferated astrocytes and those that have migrated from distal areas, and undergo isomorphic gliosis, leading to an established glial scar, while reactive astrocytes far from the site of injury eventually reacquire a quiescent state with normal morphological and functional features [19] . Therefore, the highly heterogeneous state of astrocytes that have been altered to respond to the specific injury appears to be a critical determinant of glial scar formation [20] .
Cellular Origin of Glial Scars
Glial scar formation after SCi is generally referred to as reactive astrogliosis. Most reactive astrocytes in a glial scar have two origins: those proximal to the lesion zone that experience dramatic up-regulation of cytoskeletal proteins
[such as glial fibrillary acidic protein (GFAP), vimentin and nestin], and those that acquire stem-cell properties to form new astrocytic progeny [21] . The other source is astrocytes that have migrated from a distal area to the lesion site [22] . in addition to the astrocytic origin of the astrocytes localized in the spinal cord [23] , glial scar formation also involves the activation of cells including ependymal cells, NG2-positive cells, and meningeal cells surrounding the lesion site [24] [25] [26] .
More importantly, several studies have shown that the various aforementioned cells, which are able to change their phenotypes, are eventually fated to become reactive astrocytes and are located in the glial scar [25, 27, 28] .
in the adult rodent spinal cord, stem/progenitor cells exist at two main locations: the zone proximal to the central canal and the outer circumference below the pial surface of the cord [29] . .
NG2, a membrane-spanning CSPG, is not only expressed in a population of fate-restricted oPCs but also exists on many cellular surfaces after damage to the spinal cord [32] . Previous work has provided evidence that the NG2 + cell population includes oPCs [33] , pericytes [34] , non-myelinating Schwann cells [35] , meningeal cells [36] , 
Mechanisms of Glial Scar Formation
Considerable research on the signaling pathways and molecular mediators involved in the triggering and modulation of reactive astrocytes has advanced our understanding of the important role of reactive astrogliosis . By using specific gene-deficient mice, MMP-2 and MMP-9 have been demonstrated to play a synergistic role in glial scar formation. An overt role of limiting extensive glial scarring has been found in the MMP-2-null mouse [46] , while MMP-9 is instrumental in the development of an inhibitory glial scar by increasing the migration of reactive astrocytes surrounding the lesion site [47] .
Furthermore, infusion of a recombinant extracellular MMP inducer adenovirus into the contused animal spinal cord, and, consequently, increasing the secretion of MMP-3, reduces CSPG deposition in the glial scar and improves locomotor recovery [48] .
Epidermal growth factor receptor (EGFR) EGFR,
which is undetectable in astrocytes in normal adult CNS, is upregulated in astrocytes after contusive damage to the spinal cord [49] . Further study has demonstrated that EGFR induces reactive astrocytes to migrate, undergo hypertrophy, and form a glial scar through activation of the Rheb-mToR signal pathway [50] . Deprivation of EGFR activity in mice results in malformed glial borders and larger lesions after SCi [51] . in addition, EGFR ligands, such as EGF and transforming growth factor-alpha (TGF-alpha), stimulate astrocytes to secrete CSPGs to further form the glial scar [52] . EGFR also favors the activation of microglia via the phosphorylation of MAPK and downstream mediators [53] . Hence, EGFR at the lesion area is a critical player responsible for glial scar formation during the acute stage after SCi.
Eph/Ephrins
The Eph family of receptor tyrosine kinases is well known for its role in guiding axonal growth during development. After damage to the adult spinal cord, members of the Eph family, along with their ligands (ephrins), accumulate in the proximal axon stump and reactive astrocytes and are thus implicated in glial scar formation [54] . The studies of the effects of ephrin-B2 on reactive astrocytes and EphB2 on meningeal fibroblasts demonstrate that cellular interplay mediated by ephrin-B2
and EphB2 is an early event that results in the development of a glial scar in the injured spinal cord [55] . in addition, the up-regulation of EphA4 in injured axons leads to the retraction of corticospinal axons and inhibition of axon regeneration in the weeks after a spinal lesion [56] . Notably, a study by Turnley's team showed that astrocytic gliosis and glial scars are greatly reduced in EphA4-deficient mice after a lateral spinal cord hemisection [57] . in contrast, the genetic deletion of EphA4 does not significantly alter the astroglial response or cause the development of an astroglial fibrotic scar after dorsal hemisection SCi in mice [58] . This discrepancy cannot be simply explained by the lesion models used. Turnley's team re-examined astrocytic gliosis following injury in EphA4-null mice and revealed that these mice no longer show attenuation of astrocyte reactivity, while other phenotypes, such as decreased size of the dorsal funiculus, are unaltered. They demonstrated that the change in the EphA4-mediated astroglial phenotype is associated with long-term breeding of the EphA4 colony but does not appear to be influenced by the background mouse strain [59] .
Cytoskeleton Vimentin and GFAP are the main cytoskeletal intermediate filaments of astrocytes expressed during development and adulthood, respectively. After SCi, both vimentin and GFAP are up-regulated in reactive astrocytes [60] . An analysis of mice that are genetically deficient in vimentin or GFAP showed that glial scar However, less dense scars frequently accompanied by bleeding occur in mice double-deficient in vimentin and GFAP [61] , most likely due to the impaired astrocytic motility resulting from the ablation of intermediate filaments [62] .
Moreover, the genetic absence of vimentin and GFAP also improves axonal sprouting [63] and facilitates functional recovery in the context of a spinal cord hemisection model [64] .
Transforming growth factor-beta TGF-beta expression increases immediately after SCi in the injured segment [65] .
Both TGF-beta1 and TGF-beta2 are detectable in macrophages and astrocytes, while TGF-beta1 is also neuron-associated [66] . The cellular localization and temporal expression pattern of TGF-beta after SCi suggest that early induction of TGF-beta1 at the point of SCi modulates acute inflammatory responses and glial scar formation [67] , while the later induction of TGF-beta2 indicates a regulatory role in the maintenance of the scar [68] .
Signal transducer and activator of transcription and interleukin (STAT/IL) family STAT3, which contributes
to neuro-inflammation [69] and promotes neuronal survival and regeneration [70] after SCi, is one of the most important transducers in the process of glial scar formation. A marked reduction of glial scarring and a significant improvement of locomotion occur in animals with conditional knockdown of STAT3 compared with their wild-type counterparts [71] .
Notably, the post-injury inhibition of STAT3 nuclear translocation mitigates the proliferation and migration of spinal astrocytes, suggesting that regulating STAT3
is an effective avenue to control the development and maintenance of glial scars [72, 73] . A wide spectrum of extracellular triggers is able to activate intracellular STAT3, particularly type i and ii interferons, neurocytokines, and growth factors including EGF and platelet-derived growth factor [74] . In the case of the interleukin-6 (IL-6) family, cytokines such as IL-6, leukemia inhibitory factor and ciliary neurotrophic factor, which undergo dimerization of the gp130 signal transduction subunit with other specific receptors, direct the activation of STAT3 and elicits changes in reactive astroglia and astrocytic scar formation [75] [76] [77] .
Emerging formation by IL-6 [78] .
Moreover, using knock-out mice, S100A [79] and SoX9 [80] are also reported to be directly involved in glial scar formation by promoting reactive astrocytic migration and targeting CSPG deposition, respectively. in addition, a study of PKC disruption by the inhibitor Gö6976 has linked an increase in the regeneration of dorsal column axons with the inactivation of CSPGs after dorsal spinal cord hemisection [81] . More interestingly, Bhalala et al. recently
reported that miR-21 regulates astrocytic hypertrophy and glial scar progression after SCi, which implicates epigenetic regulation as a potential therapeutic target for manipulating glial scar formation and improving functional performance [82] .
Roles of Glial Scars in SCI
in a relative sense, there are two facets of glial scar function in the injured spinal cord. At the acute and subacute stages after SCi, the glial scar serves to seclude the lesion area from healthy tissue by limiting disruption of the blood-spinal cord barrier, the amplification of an overwhelming inflammatory response [83] and massive cellular degeneration [11] . Gradually, the glial scar has its detrimental effect, which is characteristically a long-lasting physical and chemical barrier to axonal regrowth during the chronic period [84, 85] .
Influence on Axonal Growth
over the past decade, increasing evidence has attributed the failure of axonal regrowth after SCi to limited intrinsic neuronal plasticity and the local non-permissive microenvironment including myelin-associated growth inhibitors as well as the glial scar [86, 87] . inhibition of glial scar formation by deleting key signals that mediate the process has shown an overt facilitation of the affected axon regrowth. Of note, MRL/MpJ mice are a genetically inbred strain that exhibit decreased scarring and fibrosis with a rapid regenerative healing response in several somatic tissue wounds [88, 89] . Bona fide axonal regrowth, including sprouting and regeneration, has been observed in MRL/ MpJ mice with dorsal hemi-section and contusion [90, 91] .
However, there are many differences between the two studies. In the MRL/MpJ mice with mid-thoracic spinal contusion, poor locomotor recovery is accompanied by [89] . On the contrary, MRL/MpJ mice that undergo a dorsal hemisection show improved recovery of motor function, a reduced astrocytic response, and fewer micro-cavities at the injury site [90] . Although a spectrum of axonal growth-promoting molecules, such as laminin [92] and fibronectin [93] , is induced by scar tissue after damage to the spinal cord, the prominent chemical constituents secreted by reactive astrocytes, CSPGs, stimulate axonal regrowth in the inhibitory milieu [94] . Currently, the two predominant receptor protein tyrosine phosphatase (RPTP)
receptors, RPTP-sigma [95] and leukocyte common antigenrelated receptor (LAR) [85] have been identified as functional receptors of CSPGs. in RPTP-sigma-deficient mice, the regrowth of axons across the CSPG-rich glial scar has been reported in many SCi models, including those of dorsal column crush, spinal hemisection and contusion [96] . CSPG and promotes functional locomotor recovery [97] .
Regulation of Neuro-inflammation
The neuroinflammatory response includes the activation of tissue-resident microglia and the infiltration of blood-borne macrophages, further contributing to secondary damage in the spinal cord, along with glial scarring and progressive cavitation [98, 99] . in the acute stage after SCi, the single-layer by glial scarring [100] . Moreover, disruption of astroglial scar formation using astrocytic STAT3-CKo mice to augment the spread of inflammation after SCi underscores the beneficial effect of glial scars on inflammatory restriction [70] .
From a historical perspective, neuro-inflammation has a negative reputation in the context of SCi. However, increasing evidence over the past decade has changed this perception due to the existence of alternative antiinflammatory monocytes [5] . The alternative activation of mononuclear (IL-10 producing) phagocytes, in contrast to the classic phenotype of pro-inflammatory features, has a strong matrix-resolving property to degenerate the glial scar depending on the expression of the matrix-degrading enzyme MMP-13 [101, 102] . More interestingly, CSPGs, the predominant component of glial-scar ECM, directly activate microglia/macrophages via the CD44 receptor and modulate neurotrophic factor secretion by these cells during the first two days after injury [18] . These studies advance our knowledge of the interaction between glial scar formation and the neuro-inflammatory response after SCI and emphasize the synergistic impact on the reparative process, suggesting a promising strategy for controlling neuro-inflammation by manipulating glial scarring.
Targeting Glial Scars to Promote Repair after SCI
SCi, with high morbidity and poor prognosis, including paraplegia, hemiplegia and quadriplegia, is a worldwide medical problem. Clinically, in addition to surgical decompression and spinal stabilization [103] , the administration of methyl-prednisolone has been used to prevent secondary neuronal damage [104] . However, these interferences have not translated into significant functional recovery or sparing of neuronal tissue. in the past two decades, great progress has been made on the development of remedial interventions targeting the glial scar formed after traumatic damage to the spinal cord.
Physical Interventions
Low-power laser irradiation, a modified physical therapy, is used in the treatment of severely injured peripheral nervous system and CNS [105] . in SCi, regardless of whether the damage is contusive or compressive, the irradiated spinal cord reveals a prominent reduction in the extent of the astrocyte response, manifesting attenuated CSPG-matrix accumulation, glial scar and syringomyelia [106] . in addition, the conversion of a normally non-permissive environment into a friendly milieu induced by low-dose irradiation is conducive to motor recovery after SCi [107] .
Based on a study of the injured mammalian spinal cord, the instructive effect of an imposed electrical field potentially has an influence on glial scar formation after SCi [108] . More importantly, in patients with complete SCi, implantation of an oscillating field stimulator for 15 weeks allows the recording of upper-extremity somatosensoryevoked potentials at 6 weeks, 6 months, and 1 year [109] .
Pharmacological Strategies
Following SCI, the specialized microstructure of the bloodspinal cord barrier is damaged, and the permeability between spinal cord tissue and blood vessels is unrestricted until the subacute phase [110] . Thus, by harnessing this window of barrier impairment, the delivery of pharmacological agents is a feasible approach to treat SCi. Agents that have been reported to promote axonal regeneration or/and functional recovery after SCi by manipulating glial scar formation are listed in Table 2 .
Many studies have provided evidence of the growthinhibitory nature of CSPG-containing glial scars, which are primary targets for therapeutic strategies after SCi [92] . it is well-established that chondroitinase ABC (ChABC) significantly ameliorates the hostile-matrix microenvironment following SCI by enzymatically digesting the glycosaminoglycan side-chains of CSPGs and promotes functional recovery [4, 111, 112] . in accord with these findings, a recent study showed that the infusion of ChABC is also successful in restoring neuronal glycosylation to normal [113] .
However, the clinical translation of ChABC may be set back by two major challenges: (1) its poor thermostability and (2) its synthesis from an Escherichia coli origin, which may carry immunological risk [114, 115] . in addition to ChABC, there is evidence that MMPs can degrade the protein backbone of some CSPGs to restrict the formation of a glial scar [116] , and the process is associated with mitigation of a functional deficit; however, axonal dieback is an unpleasant secondary response [117] . Grimpe and Silver showed that a newly-designed DNA enzyme against xylosyltransferase-1, a critical enzyme that initiates glycosylation of the protein core of CSPGs, blocks the formation of intact glycosaminoglycan-bearing CSPGs in the glial scar and allows micro-transplanted dorsal root ganglia axons to regenerate around the core of the lesion [118] .
Decorin, a small leucine-rich proteoglycan containing only one glycosaminoglycan chain, is a versatile player in regulating glial scar formation following SCi. Minipump administration of decorin into acute stub injuries of the adult rat spinal cord inhibits neurocan, brevican, phosphacan and NG2 expression [119] . in addition, decorin is reported to attenuate glial scar formation in the rat cerebral hemisphere [120] . in accord with these findings, decorin treatment in acute SCi induces the synthesis of plasminogen/plasmin by microglia, and these are known to play major roles in degrading the inhibitory components of the glial scar and promoting CNS plasticity [121] . More interestingly, a recent study showed that decorin has the ability to directly stimulate neurons to extend axons within CSPG-or myelin-rich environments, suggestive of a coherent pharmacological base that suppresses scarformation to facilitate axonal regrowth after SCi [122] .
it is well established that anaerobic metabolism at the lesion site due to the loss of high-energy metabolites is an important contributor to secondary damage and neurological deficits [123] . Before undergoing a moderate spinal cord contusion, rats pretreated with creatine, a potent intracellular energy buffer, score better than controls
in the BBB open-field locomotor rating scale and have significantly less scar tissue surrounding the cavity [124] .
our recent study found that ethyl pyruvate, which is able to compensate for cellular ATP synthesis [125] , improves functional recovery by evoking a significant amelioration of the abnormal glial microenvironment after SCi [126] . in the damaged cord, glial scar formation is markedly reduced, whereas the number of proliferative astrocytes decreases in an astrocyte culture scratch injury model after ethyl pyruvate administration. Moreover, ethyl pyruvate affects activated microglia and CD11b-positive inflammatory cells in an anti-inflammatory fashion.
A recent study showed that the delayed expression of cell-cycle proteins contributes to astroglial scar formation and chronic inflammation after rat spinal cord contusion, suggesting that pharmacological agents against cell-cycle proteins ameliorate the non-permissive microenvironment [127] . Specifically, the use of olomoucine to inhibit cell cycle kinases (CDKs) 2 and 5 results in the persistent down-regulation of astroglia [128] and microglia [129] proliferation within the glial scar around the site of a spinal [130] . Recently, CR8, a potent and selective roscovitinederived inhibitor of CDKs that has been reported to provide neuroprotection in experimental traumatic brain injury [131] , was found to have a beneficial effect after impact contusive SCi in rats [132] . The systemic and continuous administration of CR8 limits the sustained elevation of cell-cycle proteins related to delayed astroglial scar formation and chronic inflammation, thus significantly improving the functional recovery.
There is strong evidence that rapamycin is neuroprotective and promotes functional recovery by overcoming glial-scar inhibition through inhibition of a specific signal pathway [50] . Rapamycin, an mToR-selective inhibitor, promotes autophagy and anti-inflammation, thereby playing a neuroprotective role [133] . Based on a screen of the active ingredients of Tripterygium wilfordii Hook. F., we found that triptolide reduces glial scar formation by inactivating the JAK2-STAT3 signal pathway [134] . Moreover, observations from sporadic studies suggest that compounds such as rolipram [135] , rose Bengal [136] and 7 beta-oH cholesteryloleate [137] may be beneficial in treating SCI by manipulating glial scarring.
Concluding Remarks
Glial scar formation is an important biological event after 
